September 25, 2024 11:46 AM EDTUpdated 12:59 PM
Pharma
Manufacturing

Emer­gent says it has $400M in or­ders re­lat­ed to mpox out­break 

Anna Brown

News Reporter

Emer­gent BioSo­lu­tions has se­cured around $400 mil­lion worth of or­ders for its small­pox and mon­key­pox prod­ucts, in­clud­ing its vac­cine be­ing used to help pro­tect against …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

Up­dat­ed: FDA ad­comm votes to lim­it Op­di­vo, Keytru­da use in stom­ach, esophageal can­cers based on key bio­mark­er

In­sil­i­co Med­i­cine, an ear­ly force in AI-dri­ven drug R&D, lets IPO plans pe­ter out for sec­ond year in a row

ARCH, biotech's star slug­ger, snags an­oth­er $3B for 13th fund

Flag­ship launch­es start­up to de­sign and make lipid nanopar­ti­cles for ge­net­ic med­i­cines

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times